|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model.
|
30279623 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Correction: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.
|
31350527 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations of Keap1 occurred at a much lower frequency in both preneoplastic lesions and HCCs and were mutually exclusive with those of Nrf2.
|
25783764 |
2015 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma.
|
30909929 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, similar aggregates were identified in more than 25% of human hepatocellular carcinomas (HCC), and induction of Nrf2 target genes was recognized in most of these tumors.
|
21482715 |
2011 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Consistently, the HCA/HCC lesions developed in the G6Pase-α-deficient livers display marked accumulation of p62 aggregates and phosphorylated p62 along with activation of Nrf2 and mTORC1 signaling.
|
31735334 |
2020 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results suggested that apigenin sensitizes BEL-7402/ADM cells to doxorubicin through miR-101/Nrf2 pathway, which furtherly supports apigenin as a potential chemo-sensitizer for hepatocellular carcinoma.
|
29137246 |
2017 |
|
Liver carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.
|
27650414 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC.
|
27345495 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Combination therapy in a TAA-induced HCC rat model was more effective than 5-FU or Vit D through the modulation of TGF-β1, caspase-3, and NrF2 expressions.
|
30205014 |
2018 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These emerging molecular mechanisms and the therapeutic perspective of targeting Nrf2-p62 interaction in HCC are discussed in this paper along with the prognostic value of autophagy in this type of cancer.
|
29274776 |
2018 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of our data confirmed that oxidative stress-mediated mitochondrial apoptosis (especially the Nrf-2/HO-1 pathway) is responsible for 5h2c-induced HCC damage.
|
30055129 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<i>Nrf2-lncRNA</i> levels correlated with the recurrence-free postsurgery survival rate of patients with hepatocellular carcinoma.
|
30897343 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using microarray, quantitative reverse transcription-PCR, and RNA-seq technologies, we examined the gene expression induced by PB125 in HepG2 (hepatocellular carcinoma) cells, including canonical Nrf2-regulated genes, noncanonical Nrf2-regulated genes, and genes which appear to be regulated by non-Nrf2 mechanisms.
|
31058853 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review summarizes the role and mechanism(s) of action of Nrf2 dysregulation in HCC and therapeutic options that can be employed to modulate this transcription factor.
|
30513925 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High p62 expression is needed for activation of NRF2 and mTORC1, induction of c-Myc, and protection of HCC-initiating cells from oxidative stress-induced death.
|
27211490 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells.
|
25896253 |
2015 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression of Nrf2 (n = 100) and 8-OHdG (n = 53) was remarkably increased in HCC tissues compared with the noncancerous hepatic tissues.
|
28281193 |
2017 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WES of the HCC tissue uncovered somatic driver mutations in the beta-catenin (CTNNB1) and nuclear-factor-erythroid-2-related-factor-2 (NFE2L2) genes.
|
25016225 |
2014 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features.
|
25135868 |
2014 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.
|
25556489 |
2014 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Low dose (7.5 J/m(2)) UVB exposure of mouse hepatoma, mouse keratinocyte, and human skin fibroblast cells led to the nuclear accumulation of Nrf2 and up-regulation of ARE-mediated gene expression.
|
16951152 |
2006 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Collectively, we demonstrated that SLC27A5 acts as a novel tumor suppressor by suppressing TXNRD1 expression via the KEAP1/NRF2 pathway in HCC.
|
31367013 |
2020 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this research to examine the therapeutic effects of nicotinamide against hepatocellular carcinoma (HCC) both in vivo and in vitro through affecting IGF-1 and the balance between PKB and Nrf2.
|
30784932 |
2019 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway.
|
30619751 |
2018 |